Results 91 to 100 of about 12,272 (217)

CCNE1: A Cell Cycle Regulator That Influences Tumor Progression

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACTCyclin E1 (CCNE1), a pivotal member of the cyclin family, governs the G1/S phase transition of the cell cycle by binding to and activating cyclin‐dependent kinase 2 (CDK2), thereby initiating DNA replication and driving S‐phase entry. In a broad spectrum of human malignancies—including breast, ovarian, gastric, and non‐small cell lung cancers ...
Liang Yan, Siyi Liu, Yanling Li, Qian He, Chen Long, Ning Tang, Yanhong Zhou   +6 more
wiley   +1 more source

Splicing factor SF3B1 promotes endometrial cancer progression via regulating KSR2 RNA maturation [PDF]

, 2020
Although endometrial cancer is the most common cancer of the female reproductive tract, we have little understanding of what controls endometrial cancer beyond the transcriptional effects of steroid hormones such as estrogen. As a result, we have limited
Richters, Megan M, Richters, Megan M., Popli, Pooja, Thaker, Premal H., Tycksen, Eric, Kim, Tae Hoon, Griffith, Obi, Chadchan, Sangappa B., Griffith, Malachi, Kommagani, Ramakrishna, Chadchan, Sangappa B, Thaker, Premal H   +11 more
core   +1 more source

Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower‐risk myeloid malignancies: Results from EVITA, a phase 2 randomized, placebo‐controlled trial

Cancer, Volume 132, Issue 19, 1 October 2026.
Abstract Background Vitamin C (VitC) is a cofactor for TET enzymes involved in DNA demethylation and epigenetic regulation. Mutations in TET2 are common drivers of leukemia. Preclinical studies suggest that VitC may delay leukemia progression. This study aimed to evaluate the biological activity, safety, and clinical impact of oral VitC in patients ...
Stine Ulrik Mikkelsen, Ali Al‐Mousawi, Amalie Bach Puglisi, Anders Pommer Vallentin, Astrid Østergaard Mortensen, Zachary Madaj, Toshinori Hinoue, Heidi Naomi Ottesen, Jakob Schmidt Jespersen, Linn Gillberg, Morten Tulstrup, Niels Richard Hansen, Jakob Werner Hansen, Mette Klarskov Andersen, Stacey Lyn Thomas, Christine Isaguirre, Ryan Sheldon, Marie Adams, Ryan Burgos, Stephen Baylin, Bo Kok Mortensen, Casey Lee O’Connell, Marianne Tang Severinsen, Peter William Laird, Jens Lykkesfeldt, Peter Jones, Kirsten Grønbæk   +26 more
wiley   +1 more source

SF3B1-mutant models of RNA mis-splicing uncover UBA1 as a therapeutic target in myelodysplastic neoplasms

Myelodysplastic syndromes with somatic mutations in the splicing factor SF3B1 gene (MDS-SF3B1) result in RNA mis-splicing, erythroid dysplasia and ultimately refractory anemia.
Elli Papaemmanuil (6499196), Nikolas Herold (18664402), Dimitris Kanellis (18680989), Jonas Thier (22135540), Sophia Hofmann (19569301), Eirini P Papapetrou (21670556), Vanessa Lundin (224979), Ingrid Lilienthal (481336), Pedro L Moura (22135561), Indira Barbosa (22135552), Katharina M Kirchhof (22135543), Teresa Mortera-Blanco (22135549), André G Deslauriers (22135558), Eva Hellström-Lindberg (89573), Ann-Charlotte Björklund (22135555), Jiri Bartek (138045), Gabriele Todisco (22135546)   +16 more
core   +1 more source

Functional validation of driver mutation‐specific uveal melanoma biomarkers: role of COL9A3 in cancer cell plasticity

The Journal of Pathology, Volume 270, Issue 2, Page 226-240, October 2026.
Abstract Uveal melanoma (UM) is a deadly ocular malignancy with well‐described genetic alterations that predict disease outcome. However, our current understanding of the biological underpinnings of high‐risk uveal melanoma progression remains relatively limited. Using RNA expression profiles from 250 patients with UM, we identified 12 novel biomarkers
QCC van den Bosch, RM Verdijk, H Fadlelseed, TPP van den Bosch, S Owens, S Kennedy, E Kilic, E Brosens   +7 more
wiley   +1 more source

SF3B1 mutation accelerates the development of CLL via activation of the mTOR pathway

JCI Insight
RNA splicing factor SF3B1 is one of the most recurrently mutated genes in chronic lymphocytic leukemia (CLL) and frequently co-occurs with chromosome 13q deletion [del(13q)].
Bo Zhang, Prajish Iyer, Meiling Jin, Elisa Ten Hacken, Zachary J. Cartun, Kevyn L. Hart, Mike Fernandez, Kristen Stevenson, Laura Rassenti, Emanuela M. Ghia, Thomas J. Kipps, Donna Neuberg, Ruben Carrasco, Wing C. Chan, Joo Y. Song, Yu Hu, Catherine J. Wu, Lili Wang   +17 more
doaj   +1 more source

To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy

European Journal of Haematology, Volume 117, Issue 4, Page 750-766, October 2026.
ABSTRACT Chronic lymphocytic leukemia (CLL) is most frequently diagnosed at early, asymptomatic stages (Rai 0/Binet A), in which a watch‐and‐wait strategy remains the standard of care, based on historical trials demonstrating no overall survival benefit from early treatment.
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Giovanna Cutrona, Antonella Bruzzese, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Nicola Amodio, Franco Fais, Antonino Neri, Manlio Ferrarini, Valter Gattei, Fortunato Morabito, Massimo Gentile   +16 more
wiley   +1 more source

Immunophenotypic, Genetic, and Clinical Features Associated With RUNX1 Mutation in Acute Leukemias and Chronic Myeloid Neoplasms

International Journal of Laboratory Hematology, Volume 48, Issue 5, Page 1094-1102, October 2026.
ABSTRACT Introduction RUNX1 is a commonly mutated transcriptional regulator of hematopoiesis in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Mutated RUNX1 (mRUNX1) may associate with cross‐lineage immunophenotypic aberrancy, presenting potential complications for blast lineage assignment at diagnosis. Methods Clinical and laboratory
Yi Han Xia, Eric McGinnis
wiley   +1 more source

Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis

, 2018
The World Health Organization 2016 classification of myelodysplastic syndromes (MDS) incorporates SF3B1 mutational status, in which patients with > 5% ring sideroblasts (RS) in the presence of SF3B1 mutation are classified as MDS-RS.
Steensma, David P., DeZern, Amy, John Barnard, Guillermo Garcia-Manero, Migdady, Yazan, Sekeres, Mikkael A., Najla Al Ali, Roboz, Gail, Barnard, John, Al Ali, Najla, Komrokji, Rami S., Mikkael A. Sekeres, Gail Roboz, Garcia-Manero, Guillermo, David P. Steensma, Amy DeZern, Yazan Migdady, Rami S. Komrokji   +17 more
core   +1 more source

Identification of UBA7 expression downregulation in myelodysplastic neoplasm with SF3B1 mutations

Scientific Reports
SF3B1 gene mutations are prevalent in myelodysplastic syndrome (MDS) and define a distinct disease subtype. These mutations are associated with dysregulated genes and pathways, offering potential for novel therapeutic approaches.
Sael Alatawi, Othman R. Alzahrani, Fuad A. Alatawi, Ibrahim A. Almazni, Alhomidi Almotiri, Fahad M. Almsned   +5 more
doaj   +1 more source